PDS Biotechnology Corporation
General ticker "PDSB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $91.0M (TTM average)
PDS Biotechnology Corporation does not follow the US Stock Market performance with the rate: -3.9%.
Estimated limits based on current volatility of 4.0%: low 1.28$, high 1.39$
Factors to consider:
- Current price 54.4% below estimated low
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.54$, 8.09$]
- 2024-12-30 to 2025-12-30 estimated range: [3.02$, 7.15$]
Financial Metrics affecting the PDSB estimates:
- Negative: Non-GAAP EPS, $ of -1.38 <= 0.04
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.30 <= 1.79
- Positive: 43.26 < Shareholder equity ratio, % of 44.00 <= 63.75
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0.14 <= 0.67
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -32.02 <= 0
Short-term PDSB quotes
Long-term PDSB plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $21.44MM | $41.67MM | $43.05MM |
Operating Income | $-21.44MM | $-41.67MM | $-43.05MM |
Non-Operating Income | $0.00MM | $-0.38MM | $-1.30MM |
Interest Expense | $0.00MM | $1.32MM | $4.21MM |
R&D Expense | $11.25MM | $29.43MM | $27.76MM |
Income(Loss) | $-21.43MM | $-42.05MM | $-44.35MM |
Taxes | $-4.52MM | $-1.20MM | $-1.41MM |
Profit(Loss)* | $-16.92MM | $-40.85MM | $-42.94MM |
Stockholders Equity | $63.21MM | $44.00MM | $26.13MM |
Assets | $67.20MM | $77.01MM | $59.39MM |
Operating Cash Flow | $-12.49MM | $-25.71MM | $-33.64MM |
Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
Financing Cash Flow | $48.89MM | $34.29MM | $16.38MM |
Earnings Per Share** | $-0.66 | $-1.43 | $-1.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.